Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes

Expert Opinion on Investigational Drugs

Volumn 26, Issue 9, 2017, Pages 1083-1089

  Tan, Xueying ^a   Cao, Xiaojing ^b   Zhou, Minzhi ^c   Zou, Ping ^d   Hu, Jingbo ^e  

^a ZHEJIANG PHARMACEUTICAL COLLEGE   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY CITY COLLEGE   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e ZHEJIANG UNIVERSITY   (China)

Author keywords

cardiovascular protection; glucagon like peptide 1; once weekly administration; Semaglutide; type 2 diabetes; weight loss

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; CARDIOVASCULAR RISK; DIABETIC PATIENT; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; WEIGHT REDUCTION; AGONISTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; METABOLISM; PATHOPHYSIOLOGY;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE;

EID: 85026777421     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2017.1360274     Document Type: Article

References (54)

1. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl. 1):S1–S49.
2. Tropeano AI., Mechanism of diabetic complications:“therapeutic” perspectives. Ann Endocrinol (Paris). 2003;64:474–476.
3. CDC, Department of health and human services [homepage on the Internet]. National diabetes statistics report, 2014. updated 2014; cited 2015 May15. Available from:http://www.cdc.gov//diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed 2014 Sept 28
4. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, Belgium; 2013.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
6. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus:a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772.
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015:a patient-centered approach:update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
8. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Jama. 1999;281:2005–2012.
9. Deacon CF, Lebovitz HE., A comparative review of DPP-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2015 Nov 24. [Epub ahead of print] Review. DOI:10.1111/dom.12610
10. Vilsbøll T. The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab. 2009;11(Suppl 3):11–18.
11. Baggio LL, Drucker DJ. Biology of incretins:GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.
12. Iepsen EW, Torekov SS, Holst JJ. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Expert Opin Pharmacother. 2014;15:2487–2500.
13. Montanya E. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012;13(10):1451–1467.
14. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742.
15. Nauck MA, Petrie JR, Sesti G. The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes. Diabetologia. 2012;55(Suppl1):S72-OP.
16. Gotfredsen CF, Molck AM, Thorup I, et al. The human GLP-1 analogs liraglutide and semaglutide:absence of histopathological effects on the pancreas in nonhuman primates. Diabetes. 2014;63:2486–2497.
17. Marbury TC, Flint A, Segel S, et al. Pharmacokinetics and tolerability of a single dose of semaglutide, a once-weekly human GLP-1 analog, in subjects with and without renal impairment. Diabetologia. 2014;57(Suppl. 1):S358.• Pharmacokinetic and pharmacodynamics evaluation on semaglutide.
18. Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55:497–504.
19. Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39:231–241.•• Dose-raging study of semaglutide.
20. Sorli C, Harashima S-I, Tsoukas G, et al. OR15-1 efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1). 98th Annual Meeting of the Endocrine Society (ENDO); 2016 Apr 6; Boston.
21. NCT02054897. Efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes (SUSTAIN™1). Accessed 2016 Aug20. Available from: https://clinicaltrials.gov/ct2/show/NCT02054897
22. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.•• Semaglutide treatment on cardiovascular events.
23. NCT01923181. Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes. Accessed 2016 Aug20. Available from: https://clinicaltrials.gov/ct2/show/NCT01923181
24. Steinert RE, Poller B, Castelli MC, et al. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther. 2009;86:644–650.
25. NCT02773381. A trial investigating the effect of oral semaglutide compared with placebo on postprandial glucose and triglyceride metabolism, energy intake, appetite sensations and gastric emptying in subjects with type 2 diabetes. Accessed 2016 Aug20. Available from: https://clinicaltrials.gov/ct2/show/NCT02773381
26. NCT02827708. Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment (PIONEER 5). Accessed 2016 Aug20. Available from: https://clinicaltrials.gov/ct2/show/NCT02827708
27. NCT02692716. A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes (PIONEER 6). Accessed 2016 Aug20. Available from: https://clinicaltrials.gov/ct2/show/NCT02692716
28. NCT02863419. Efficacy and safety of oral semaglutide versus liraglutide and versus placebo in subjects with type 2 diabetes mellitus (PIONEER 4). Accessed 2016 Aug20. Available from: https://clinicaltrials.gov/ct2/show/NCT02863419
29. NCT02607865. Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes (PIONEER 3). Accessed 2016 Aug20 Available from: https://clinicaltrials.gov/ct2/show/NCT02607865
30. NCT02863328. Efficacy and safety of oral semaglutide versus empagliflozin in subjects with type 2 diabetes mellitus (PIONEER 2). Accessed 2016 Aug20 Available from: https://clinicaltrials.gov/ct2/show/NCT02863328
31. Stonehouse AH, Holcombe JH, Kendall DM. Management of Type 2 diabetes:the role of incretin mimetics. Expert Opin Pharmacother. 2006;7:2095–2105.
32. Ismail-Beigi F. Glycemic management of type 2 diabetes mellitus. N Engl J Med. 2012;366:1319–1327.
33. Chen WR, Shen XQ, Zhang Y, et al. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 2016;52:516–526.
34. Mikhail N. Effects of incretin-based therapy in patients with heart failure and myocardial infarction. Endocrine. 2014;47:21–28.
35. Lesven S, Gautier JF, Maréchaud R. Treatment of type 2 diabetes:new clinical studies and effects of GLP-1 on macrovascular complications. Ann Endocrinol (Paris). 2010;71:505–510.
36. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110.
37. Tan X, Hu J. Combination therapy for type 2 diabetes:dapagliflozin plus metformin. Expert Opin Pharmacother. 2016;17:117–126.
38. Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes:new and future developments in treatment. Lancet. 2011;378:182–197.
39. Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the UK primary care setting. Diabetes Care. 2005;28:20–26.
40. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes a retrospective cohort study. Diabetes Care. 2003;26:2983–2989.
41. Pantalone KM, Kattan MW, Yu C, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas:a retrospective analysis. Acta Diabetol. 2009;46:145–154.
42. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146–151.
43. Athyros VG, Katsiki N, Tentolouris N. Editorial:do some glucagon-like-peptide-1 receptor agonists (GLP-1 RA) reduce macrovascular complications of type 2 diabetes mellitus a commentary on the Liraglutide Effect and Action in Diabetes:evaluation of Cardiovascular Outcome Results (LEADER) Trial. Curr Vasc Pharmacol. 2016;14:469–473.
44. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962–965.
45. Liu R, Li L, Chen Y, et al. Effects of glucagon-like peptide-1 agents on left ventricular function:systematic review and meta-analysis. Ann Med. 2014;46:664–671.
46. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
47. Lorenz M, Lawson F, Owens D, et al. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017;16:6.
48. NCT03007329. Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus. (EXENDA). Accessed 2016 Aug20 Available from: https://clinicaltrials.gov/ct2/show/NCT03007329
49. NCT02777073. Effects of single doses of liraglutide and dapagliflozin on hyperglycemia and ketogenesis in type 1 diabetes (1974). Accessed 2016 Aug20 Available from: https://clinicaltrials.gov/ct2/show/NCT02777073
50. Abdulsalim S, Peringadi Vayalil M, Miraj SS. New fixed dose chemical combinations:the way forward for better diabetes type II management? Expert Opin Pharmacother. 2016;17:2207–2214.
51. Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8):a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:1004–1016.
52. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
53. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
54. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 Inhibitor. Diabetes Obes Metab. 2017 Apr 22. [Epub ahead of print]. DOI:10.1111/dom.12982